Elicera Therapeutics AB (publ) (STO:ELIC)

Market Cap	244.13M +205.1%
Revenue (ttm)	13.70M +219.6%
Net Income	-13.04M
EPS	-0.31
Shares Out	48.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,545
Average Volume	177,249
Open	5.14
Previous Close	5.13
Day's Range	4.96 - 5.19
52-Week Range	2.05 - 8.43
Beta	0.38
RSI	38.53
Earnings Date	Feb 13, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ELIC

Financial Performance

In 2024, Elicera Therapeutics AB's revenue was 7.13 million, a decrease of -36.52% compared to the previous year's 11.23 million. Losses were -16.11 million, -1.75% less than in 2023.